STEM CELL TRANSPLANTATION; IRANIAN EXPERIENCE

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

GHAVAMZADEH ARDESHIR; ALI MOGHADAM K.; JAHANI M.; MOUSAVI S.A.A.; IRAVANI M.; BAHAR B.; KHODABANDEH A.; KHATAMI F.; GHAFARI FATEMEH; JALALI ARASH

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: ARCHIVES OF IRANIAN MEDICINE Year:2009 | Volume:12 | Issue:1 Page(s): 69-72

Download Full-Text

View:

449

Download:

435

Cites:

Information Journal Paper

Title

STEM CELL TRANSPLANTATION; IRANIAN EXPERIENCE

Author(s)

Keywords

ALLOGENEIC

AUTOLOGOUS

STEM CELL TRANSPLANTATION

Abstract

From March 1991 through 31st December 2007, 2042 patients underwent STEM CELL TRANSPLANTATION at the Hematology-Oncology and STEM CELL TRANSPLANTATION Research Center, affiliated to Tehran University of Medical Sciences. These transplantations included 1405 ALLOGENEIC STEM CELL TRANSPLANTATION, 624 AUTOLOGOUS STEM CELL TRANSPLANTATION, and 13 syngeneic STEM CELL TRANSPLANTATION. STEM CELL TRANSPLANTATION was performed for various diseases including acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphoblastic leukemia, thalassemia major, sickle cell thalassemia, sickle cell disease, multiple myeloma, myelodysplasia, mucopolysaccharidosis, paroxysmal nocturnal hemoglobinuria, non-Hodgkin’s lymphoma, Hodgkin’s disease, severe aplastic anemia, plasma cell leukemia, Niemann-Pick disease, Fanconi anemia, severe combine immunodeficiency, congenital neutropenia, leukocyte adhesion deficiencies, Chediak-Higashi syndrome, osteopetrosis, histiocytosis X, Hurler syndrome, amyloidosis, systemic sclerosis, breast cancer, Ewing's sarcoma, testicular cancer, germ cell tumors, neuroblastoma, medulloblastoma, renal cell carcinoma, nasopharyngeal carcinoma, ovarian cancer, Wilms’ tumor, rhabdomyosarcoma, pancreatoblastoma, and multiple sclerosis. We had 105 cellular therapies for postmyocardial infarction, multiple sclerosis, cirrhosis, head of femur necrosis, and renal cell carcinoma. About 30 patients were retransplanted in this center. About 74.9% of the patients (1530 of 2042) remained alive between one to 168 months after STEM CELL TRANSPLANTATION. Nearly 25.1% (512 of 2042) of our patients died after STEM CELL TRANSPLANTATION. The causes of deaths were relapse, infections, hemorrhagic cystitis, graft versus host disease, and others.

Cites

No record.

References